Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S.

SEOUL (Reuters) - South Korean biosimilars maker Samsung Bioepis Co Ltd said on Tuesday it has applied to the U.S. Food and Drug Administration (FDA) for approval to sell its version of blockbuster drug Remicade in the world's biggest healthcare market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news